Jivi (Damoctocog Alfa Pegol)

Jivi is used within the hemophilia A treatment pathway to restore clotting function.

• Hemophilia A (congenital factor VIII deficiency) – prophylaxis of bleeding episodes: maintains sufficient factor VIII levels to reduce spontaneous bleeds.
• Hemophilia A – on‑demand treatment of acute bleeding episodes: provides rapid factor VIII activity to stop active bleeding.
• Hemophilia A during surgery – peri‑operative hemostasis: supplies factor VIII to achieve adequate clot formation during surgical procedures.

• Damoctocog alfa pegol is a PEGylated recombinant factor VIII protein that circulates in the plasma and replaces the missing endogenous factor VIII. By binding to activated factor IX, it restores the intrinsic tenase complex, enabling activation of factor X, generation of thrombin, and formation of a stable fibrin clot, thereby correcting the coagulation defect in hemophilia A patients.

Jivi may be associated with adverse reactions following intravenous administration.

Common Side Effects

• Infusion site erythema or pain
• Headache
• Fever or chills
• Nausea or abdominal discomfort
• Fatigue or malaise

Serious or Rare Side Effects

• Development of inhibitory antibodies against factor VIII
• Anaphylactic or severe hypersensitivity reactions
• Thromboembolic events such as deep‑vein thrombosis
• Hepatic enzyme elevations
• Hemolysis or renal impairment

Prior to initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

• Monitor inhibitor development: perform regular factor VIII activity assays.
• Assess for allergic reactions: observe patients during and after infusion.
• Avoid use in patients with known hypersensitivity to PEGylated proteins.
• Use caution in individuals with a history of thrombosis: evaluate risk factors.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Jivi can interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid)

• Concurrent use of bypassing agents (e.g., activated prothrombin complex concentrate) may increase thrombotic risk.
• Co‑administration with anticoagulants (warfarin, DOACs) can reduce hemostatic efficacy.
• Simultaneous infusion of other factor VIII products may provoke immune sensitisation.

Moderate Interactions (Monitor Closely)

• Live vaccines may have altered immunogenicity; monitor response.
• Immunosuppressive therapy could affect inhibitor formation; assess regularly.
• High‑dose intravenous immunoglobulin may interfere with factor VIII activity assays.